The stock of BioLineRx Ltd. (NASDAQ:BLRX) last traded at $0.67, down -1.18% from the previous session.
Data from the available sources indicates that BioLineRx Ltd. (NASDAQ:BLRX) is covered by 2 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $4.00, we find $6.00. Given the previous closing price of $0.68, this indicates a potential upside of 782.35 percent. BLRX stock price is now 0.06% away from the 50-day moving average and -41.66% away from the 200-day moving average. The market capitalization of the company currently stands at $42.89M.
In total, 0 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $9.67 as their price target over the next twelve months.
With the price target enhanced from $1 to $3, Maxim Group Upgraded its rating from Hold to Buy for BioLineRx Ltd. (NASDAQ: BLRX). On February 13, 2017, Rodman & Renshaw recently initiated its ‘Buy’ rating on the stock quoting a target price of $3, while ‘Maxim Group’ rates the stock as ‘Hold’.
There have been several recent changes in the stakes of large investors in BLRX stock. A new stake in BioLineRx Ltd. shares was purchased by ALTIUM CAPITAL MANAGEMENT LP during the first quarter worth $2,780,000. SABBY MANAGEMENT, LLC invested $2,033,000 in shares of BLRX during the first quarter. In the first quarter, ARMISTICE CAPITAL, LLC acquired a new stake in BioLineRx Ltd. valued at approximately $1,874,000. APOLLON WEALTH MANAGEMENT, LLC acquired a new stake in BLRX for approximately $33,000. TWO SIGMA SECURITIES, LLC purchased a new stake in BLRX valued at around $20,000 in the second quarter. In total, there are 33 active investors with 19.40% ownership of the company’s stock.
With an opening price of $0.6700 on Monday morning, BioLineRx Ltd. (NASDAQ: BLRX) set off the trading day. During the past 12 months, BioLineRx Ltd. has had a low of $0.55 and a high of $1.98. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 7.10, and a quick ratio of 7.10. The fifty day moving average price for BLRX is $0.6672 and a two-hundred day moving average price translates $1.1434 for the stock.
The latest earnings results from BioLineRx Ltd. (NASDAQ: BLRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.15, missing analysts’ expectations of -$0.11 by -0.04. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $7.08 million for the quarter, compared to $6.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.85 percent.
BioLineRx Ltd.(BLRX) Company Profile
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi’in, Israel.